ClinicalTrials.gg
Active, not recruitingNCT05445843KontRASt-06Updated Oct 8, 2026Results posted

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

A Phase 2 interventional study of JDQ443 in Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 45 sites in 19 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Updated Oct 8, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Lung Neoplasms by Novartis — 2 open to participants now, 5 under way, none of them phase 3. Lung Neoplasms · Novartis.

Enrollment
18th of 36
95 · median 95
Started
2022
with 3 others
Phase 2
14 of 40
none open now
Registered
37th of 40
by date

Among the 40 studies in Lung Neoplasms by Novartis, this one is the 18th largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 in phase 2, and was the 37th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 40 studies in Lung Neoplasms by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lung Neoplasms by Novartis, or all of them as a file.
02

Study summary

This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and have a PD-L1 expression \< 1% (cohort A) or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).

Read the detailed description

This is a non-randomized, open-label, single-arm, multicenter, phase II study evaluating the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic KRAS G12C-mutated NSCLC.

The study will have 2 non-comparative cohorts that will recruit participants in parallel according to the following characteristics:

  • Cohort A: participants whose tumors harbor a KRAS G12C mutation and a PD-L1 expression \< 1%, regardless of STK11 mutation status (N=90).
  • Cohort B: participants whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥ 1% and an STK11 co-mutation (N=30).

The study treatment begins on Cycle 1 Day 1 (C1D1) with the first administration of JDQ443. One treatment cycle consists of 21 (±3) days.

Study completion is defined as the earliest occurrence of one of the following:

  • The last participant completes last study visit (and the assessments associated with this visit have been documented and followed-up appropriately by the Investigator), dies, withdraws consent, or is lost to follow-up, whichever comes first.]
  • In the event of an early study termination decision, the date of that decision.
  • Another clinical study becomes available that can continue to provide JDQ443 to study participants and all participants with ongoing treatment are transferred to that clinical study.
03

Conditions studied

  • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Browse trials for

Keywords

  • Lung cancer
  • NSCLC
  • KRAS G12C
  • STK11
  • PD-L1
  • JDQ443
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria

  • confirmed locally advanced (stage IIIb/IIIc not eligible for definitive chemoradiation or surgical resection with curative intent) or (stage IV) NSCLC without previous systemic treatment for metastatic disease. Prior (neo) treatment with chemotherapy and/or immunotherapy, or prior radiotherapy administered sequentially or concomitantly with chemotherapy and/or immunotherapy for localized or locally advanced disease are accepted if the time between therapy completion and enrollment is > 12 months.
  • Presence of a KRAS G12C mutation (all participants) and:

    • Cohort A: expression \< 1%, regardless of STK11 mutation status
    • Cohort B: PD-L1 expression ≥ 1% and an STK11 co-mutation
  • At least one per 1.1.
  • performance status ≤ 1.
  • Participants capable of swallowing study medication.

Key Exclusion criteria

  • Participants whose tumors harbor an EGFR-sensitizing mutation and/or ALK rearrangement by local laboratory testing. Participants with other known druggable alterations will be excluded, if required by local guidelines
  • Previous use of a KRAS G12C inhibitor or previous systemic treatment for metastatic NSCLC.
  • A medical condition that results in increased photosensitivity (i.e., solar urticaria, lupus erythematosus, etc.).
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Participants who are taking a prohibited medication (strong inducers) that cannot be discontinued at least seven days prior to the first dose of study treatment and for the duration of the study.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Cohort A- PD-L1<1%

    Participants whose tumors harbor a KRAS G12C mutation and a PD-L1 expression \< 1%, regardless of STK11 mutation status.

    Drug: JDQ443

  • Experimental
    Cohort B- PD-L1≥ 1% and STK11 mutation

    Participants whose tumors harbor a KRAS G12C mutation, a PD-L1 expression ≥ 1% and an STK11 co-mutation.

    Drug: JDQ443

Interventions

  • DrugJDQ443

    JDQ443 per os (PO) 200 mg twice a day continuously

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) as Determined by the Investigator in Cohort A

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A.

    Time frame: Up to approximately 22 months

Secondary outcomes

  1. Key Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B

    Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B.

    Time frame: Up to approximately 22 months

  2. Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria

    The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs), through the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent Adverse Events (TEAEs) in this study are defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose of study treatment, or events that are present prior to the first dose of treatment and increase in severity based on preferred term within 30 days after the last study treatment.

    Time frame: Up to approximately 59 months

  3. Plasma JDQ443 Concentration in All Participants

    JDQ443 concentration data of all participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  4. Plasma JDQ443 Concentration in Chinese Participants

    JDQ443 concentration data of Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  5. Plasma JDQ443 Concentration in Non-Chinese Participants

    JDQ443 concentration data of non-Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  6. Observed Maximum Plasma Concentration (Cmax) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Cmax was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  7. Time to Reach Maximum Plasma Concentration (Tmax) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tmax was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  8. Time to Last Nonzero Plasma Concentration (Tlast) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tlast was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  9. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUC∞ was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  10. Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUClast was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  11. Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) of JDQ443

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUCτ was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

  12. Total Body Clearance (CL/F) of JDQ443 in Plasma

    Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. CL/F was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.

07

Results

Posted Oct 9, 2025

Participant flow

The study is conducted globally across 19 countries.

Participant flow — Overall Study
MilestoneCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
Started7223
Pharmacokinetic analysis set (pas)6923
Full pharmacokinetic analysis set (fpas)149
Treatment ongoing255
Discontinued from treatment and continued in the follow-up period3210
Discontinued from treatment and did not enter the follow-up period158
Completed00
Not completed7223
Withdrew: Treatment ongoing at the time of the data cut-off date 04nov2024255
Withdrew: Progressive disease179
Withdrew: Physician decision164
Withdrew: Death63
Withdrew: Subject decision62
Withdrew: Adverse event20

Outcome measures

PrimaryOverall Response Rate (ORR) as Determined by the Investigator in Cohort A

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort A.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage (%) of participants
Overall Response Rate (ORR) as Determined by the Investigator in Cohort A
Percentage (%) of participantsCohort A- PD-L1<1%
Overall Response Rate (ORR) as Determined by the Investigator in Cohort A29.2 (19.0 to 41.1)
SecondaryKey Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B

Overall Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as best overall response (BOR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the Investigator in Cohort B.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage (%) of participants
Key Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B
Percentage (%) of participantsCohort B- PD-L1≥ 1% and STK11 Mutation
Key Secondary Outcome Measure: Overall Response Rate (ORR) as Determined by the Investigator in Cohort B21.7 (7.5 to 43.7)
SecondaryNumber of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria

The distribution of adverse events will be done via the analysis of frequencies for treatment emergent Adverse Event (TEAEs) and Serious Adverse Event (TESAEs), through the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent Adverse Events (TEAEs) in this study are defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose of study treatment, or events that are present prior to the first dose of treatment and increase in severity based on preferred term within 30 days after the last study treatment.

Time frame:
Up to approximately 59 months

Results for this outcome have not been posted.

SecondaryPlasma JDQ443 Concentration in All Participants

JDQ443 concentration data of all participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · ng/mL
Plasma JDQ443 Concentration in All Participants
ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
Cycle 1 Day 1 (predose/0hour)0 ± 00 ± 0
Cycle 1 Day 1 (4 hours)3170 ± 80.84980 ± 59.8
Cycle 1 Day 1 (6 hours)2970 ± 65.64190 ± 65.7
Cycle 1 Day 15 (predose/0hour)1580 ± 96.81490 ± 97.5
Cycle 1 Day 15 (1 hour)2440 ± 102.03390 ± 89.3
Cycle 1 Day 15 (2 hours)3290 ± 82.74700 ± 81.8
Cycle 1 Day 15 (3 hours)3770 ± 70.45540 ± 41.7
Cycle 1 Day 15 (4 hours)3290 ± 61.04330 ± 54.5
Cycle 1 Day 15 (6 hours)2810 ± 69.73600 ± 59.9
Cycle 1 Day 15 (8 hours)2260 ± 92.93120 ± 55.4
Cycle 1 Day 15 (12 hours)1780 ± 120.52380 ± 72.7
Cycle 3 Day 1 (predose/0hour)1060 ± 160.91090 ± 178.0
Cycle 5 Day 1 (predose/0hour)1000 ± 73.61320 ± 118.4
Cycle 7 Day 1 (predose/0hour)948 ± 74.21400 ± 99.4
SecondaryPlasma JDQ443 Concentration in Chinese Participants

JDQ443 concentration data of Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · ng/mL
Plasma JDQ443 Concentration in Chinese Participants
ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
Cycle 1 Day 1 (predose/0hour)0 ± 00 ± 0
Cycle 1 Day 1 (4 hours)3480 ± 41.12890 ± 110.9
Cycle 1 Day 1 (6 hours)3220 ± 26.72730 ± 92.7
Cycle 1 Day 15 (predose/0hour)1670 ± 95.71410 ± 113.8
Cycle 1 Day 15 (1 hour)2650 ± 164.11470 ± 249.7
Cycle 1 Day 15 (2 hours)3400 ± 92.32330 ± 252.3
Cycle 1 Day 15 (3 hours)5390 ± 106.94120 ± 92.0
Cycle 1 Day 15 (4 hours)3130 ± 114.63130 ± 95.2
Cycle 1 Day 15 (6 hours)2830 ± 112.62670 ± 97.3
Cycle 1 Day 15 (8 hours)4410 ± 74.82630 ± 133.1
Cycle 1 Day 15 (12 hours)4290 ± 53.42600 ± 164.4
Cycle 3 Day 1 (predose/0hour)1110 ± 42.4949 ± 142.6
Cycle 5 Day 1 (predose/0hour)650 ± 42.91050 ± 174.6
Cycle 7 Day 1 (predose/0hour)1530 ± 60.91150 ± 181.6
SecondaryPlasma JDQ443 Concentration in Non-Chinese Participants

JDQ443 concentration data of non-Chinese participants were reported separately for each of the two cohorts and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · ng/mL
Plasma JDQ443 Concentration in Non-Chinese Participants
ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
Cycle 1 Day 1 (predose/0hour)0 ± 00 ± 0
Cycle 1 Day 1 (4 hours)3140 ± 85.55760 ± 34.9
Cycle 1 Day 1 (6 hours)2940 ± 69.84840 ± 49.9
Cycle 1 Day 15 (predose/0hour)1570 ± 98.11510 ± 97.5
Cycle 1 Day 15 (1 hour)2400 ± 103.14480 ± 23.1
Cycle 1 Day 15 (2 hours)3270 ± 87.45930 ± 23.8
Cycle 1 Day 15 (3 hours)3500 ± 67.26120 ± 23.9
Cycle 1 Day 15 (4 hours)3300 ± 55.94910 ± 31.2
Cycle 1 Day 15 (6 hours)2810 ± 66.24010 ± 43.4
Cycle 1 Day 15 (8 hours)1950 ± 89.43300 ± 41.00
Cycle 1 Day 15 (12 hours)1460 ± 116.02320 ± 62.3
Cycle 3 Day 1 (predose/0hour)1050 ± 175.91180 ± 217.6
Cycle 5 Day 1 (predose/0hour)1030 ± 74.71550 ± 90.5
Cycle 7 Day 1 (predose/0hour)917 ± 74.41500 ± 85.1
SecondaryObserved Maximum Plasma Concentration (Cmax) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Cmax was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · ng/mL
Observed Maximum Plasma Concentration (Cmax) of JDQ443
ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants4170 ± 59.85160 ± 52.4
Chinese participants6010 ± 82.54320 ± 103.0
non-Chinese participants3920 ± 57.55430 ± 45.7
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tmax was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Median · Hours
Time to Reach Maximum Plasma Concentration (Tmax) of JDQ443
HoursCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants2.96 (0.967 to 9.50)3.00 (1.00 to 10.8)
Chinese participants3.58 (3.05 to 4.10)3.61 (3.13 to 4.08)
non-Chinese participants2.61 (0.967 to 9.50)2.98 (1.00 to 10.8)
SecondaryTime to Last Nonzero Plasma Concentration (Tlast) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. Tlast was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Median · Hours
Time to Last Nonzero Plasma Concentration (Tlast) of JDQ443
HoursCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants10.1 (6.00 to 16.9)11.1 (10.0 to 21.0)
Chinese participants11.9 (11.6 to 12.2)11.2 (11.1 to 11.4)
non-Chinese participants10.1 (6.00 to 16.9)11.0 (10.0 to 21.0)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUC∞ was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC∞) of JDQ443
hr*ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants33400 ± 69.041800 ± 21.7
non-Chinese participants33400 ± 69.041800 ± 21.7
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUClast was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of JDQ443
hr*ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants29100 ± 79.344200 ± 47.6
Chinese participants52700 ± 84.733500 ± 137.2
non-Chinese participants26400 ± 75.747900 ± 25.5
SecondaryArea Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) of JDQ443

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. AUCτ was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · hr*ng/mL
Area Under the Plasma Concentration-time Curve During a Dosage Interval (AUCτ) of JDQ443
hr*ng/mLCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants34500 ± 69.442700 ± 50.6
Chinese participants53500 ± 79.235400 ± 135.1
non-Chinese participants31600 ± 67.445100 ± 35.0
SecondaryTotal Body Clearance (CL/F) of JDQ443 in Plasma

Pharmacokinetic (PK) parameters were calculated based on JDQ443 plasma concentrations and actual sampling time points. PK parameters were reported separately for all participants, non-Chinese participants, and Chinese participants in each of the two cohorts. CL/F was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 1 (predose/0hour, 4 hours and 6 hours), Cycle 1 Day 15 (predose/0hour, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 12 hours). Cycles 3, 5 and 7 Day 1 (predose/0hour). 1 cycle = 21 days.
Reported as:
Geometric mean · mL/hr
Total Body Clearance (CL/F) of JDQ443 in Plasma
mL/hrCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
All participants5800 ± 69.44680 ± 50.6
Chinese participants3730 ± 79.25650 ± 135.1
non-Chinese participants6340 ± 67.44440 ± 35.0

Adverse events

Collected over From first dose of study treatment up to the cut-off date for the primary analysis (04-Nov-2024), approximately 22 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A- PD-L1<1%15/72 (20.8%)29/72 (40.3%)60/72 (83.3%)
Cohort B- PD-L1≥ 1% and STK11 Mutation4/23 (17.4%)10/23 (43.5%)21/23 (91.3%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
PneumoniaInfections and infestations5/722/23
SepsisInfections and infestations1/722/23
DyspnoeaRespiratory, thoracic and mediastinal disorders5/722/23
Pericardial effusionCardiac disorders2/721/23
DiarrhoeaGastrointestinal disorders0/721/23
PyrexiaGeneral disorders and administration site conditions0/721/23
Hepatic cytolysisHepatobiliary disorders0/721/23
Neck painMusculoskeletal and connective tissue disorders0/721/23
Acute kidney injuryRenal and urinary disorders0/721/23
AtelectasisRespiratory, thoracic and mediastinal disorders0/721/23
Most frequent other events
Showing 10 of 49
Most frequent other events
EventCohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 Mutation
AnaemiaBlood and lymphatic system disorders21/724/23
DiarrhoeaGastrointestinal disorders19/721/23
ConstipationGastrointestinal disorders12/726/23
NauseaGastrointestinal disorders18/725/23
Oedema peripheralGeneral disorders and administration site conditions13/725/23
Weight decreasedInvestigations8/725/23
AstheniaGeneral disorders and administration site conditions14/723/23
DyspnoeaRespiratory, thoracic and mediastinal disorders14/722/23
FatigueGeneral disorders and administration site conditions13/724/23
Alanine aminotransferase increasedInvestigations5/724/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 MutationTotal
Mean67.7 ± 7.6863.7 ± 10.2966.7 ± 8.50
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 MutationTotal
Female25530
Male471865
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A- PD-L1<1%Cohort B- PD-L1≥ 1% and STK11 MutationTotal
White571370
Asian11718
Unknown437
08

Study locations

45 sites
  • The Brown University Oncology Group
    Providence, Rhode Island 02903, United States
  • Novartis Investigative Site
    Pilar, Buenos Aires B1629AHJ, Argentina
  • Novartis Investigative Site
    Córdoba, Córdoba Province X5016KEH, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1426AGE, Argentina
  • Novartis Investigative Site
    Córdoba, X5000JHQ, Argentina
  • Novartis Investigative Site
    Feldkirch, 6807, Austria
  • Novartis Investigative Site
    Wels, 4600, Austria
  • Novartis Investigative Site
    Sint-Niklaas, Oost Vlaanderen 9100, Belgium
  • Novartis Investigative Site
    Roeselare, West-Vlaanderen 8800, Belgium
  • Novartis Investigative Site
    Salvador, Estado de Bahia 40170-110, Brazil
  • Novartis Investigative Site
    Belo Horizonte, 30360-680, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 22271-110, Brazil
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Changsha, Hunan 410013, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Marseille, Bouches Du Rhone 13915, France
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Montpellier, 34070, France
  • Novartis Investigative Site
    Saint-Herblain, 44805, France
  • Novartis Investigative Site
    Strasbourg, 67091, France
  • Novartis Investigative Site
    Kempten (Allgäu), Bavaria 87439, Germany
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06120, Germany
  • Novartis Investigative Site
    Hamburg, 21075, Germany
  • Novartis Investigative Site
    Oldenburg, 26121, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Athens, 11526, Greece
  • Novartis Investigative Site
    Mátraháza, 3200, Hungary
  • Novartis Investigative Site
    Thellakom Kottayam, Kerala 686016, India
  • Novartis Investigative Site
    Varanasi, Uttar Pradesh 221005, India
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Roma, RM 00128, Italy
  • Novartis Investigative Site
    Orbassano, TO 10043, Italy
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Breda, North Brabant 4818 CK, Netherlands
  • Novartis Investigative Site
    Leeuwarden, Provincie Friesland 8934 AD, Netherlands
  • Novartis Investigative Site
    Porto, 4100-180, Portugal
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Istanbul, Bagcilar 34214, Turkey (Türkiye)
  • Novartis Investigative Site
    Diyarbakır, Sur 21280, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Yenimahalle 06500, Turkey (Türkiye)
  • Novartis Investigative Site
    Torquay, TQ2 7AA, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Nov 2024, 22 months.

Results were first posted in Oct 2025, 11 months after primary completion.

Of 77 industry-sponsored phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's 22 months is below that.

Counting every sponsor, half of 364 studies reached it within 65 months; a quarter within 34 and three quarters within 105.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Oct 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 6, 2022
StartActual
Dec 6, 2022
Primary completionActual
Nov 4, 2024
CompletionEst.
Oct 28, 2026was Dec 2026
Results first posted
Oct 9, 2025
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 31, 2026→Oct 28, 2026
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Study completion Dec 31, 2026→Oct 28, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05445843
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Dec 6, 2022
Primary completion
Nov 4, 2024
Completion
Oct 28, 2026 (estimated)
Results posted
Oct 9, 2025
Last update
Oct 8, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JDQ443

Start the discussion